BlossomHill Therapeutics, Inc. (BLSM) Reports $24.0M Q3 Net Loss; Cash Runway Into Q2 2028

BlossomHill reported a Q3 2026 net loss of $24.0M, or $1.29 per share, versus $16.0M, or $6.54 per share, in Q3 2025. It had $224.9M in cash at September 30, 2026, which it expects to fund operations into Q2 2028.Material DetailsContext by AI AnalystThis is an early-stage clinical biotech update fo…